During the past decade, Groupe Hospitalier Pellegrin conducted 27 clinical trials. In the 10-year time frame, 27 clinical trials started and 9 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 15 clinical trials started and 4 clinical trials were completed. i.e. 26.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Groupe Hospitalier Pellegrin" #1 sponsor was "Hoffmann-La Roche" with 5 trials, followed by "ANRS, Emerging Infectious Diseases" with 3 trials sponsored, "Hospices Civils de Lyon" with 3 trials sponsored, "University Hospital, Bordeaux" with 3 trials sponsored and "Centre Hospitalier Universitaire Dijon" with 3 trials sponsored. Other sponsors include 28 different institutions and companies that sponsored additional 32 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Groupe Hospitalier Pellegrin" #1 collaborator was "Prothena Biosciences Limited" with 2 trials as a collaborator, "Duke Clinical Research Institute" with 1 trials as a collaborator, "European Cardiovascular Research Center" with 1 trials as a collaborator, "Federation of Medical Specialties" with 1 trials as a collaborator and "Floralis" with 1 trials as a collaborator. Other collaborators include 3 different institutions and companies that were collaborators in the rest 13 trials.

According to Clinical.Site data, the most researched conditions in "Groupe Hospitalier Pellegrin" are "Prostate Cancer" (4 trials), "Intracranial Aneurysm" (3 trials), "Alzheimer Disease" (2 trials), "Benign Neuronal Desease" (2 trials) and "Coronavirus Disease (COVID-19)" (2 trials). Many other conditions were trialed in "Groupe Hospitalier Pellegrin" in a lesser frequency.

Most popular intervention types in "Groupe Hospitalier Pellegrin" are "Drug" (23 trials), "Other" (12 trials), "Device" (9 trials), "Procedure" (5 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "MRI" (2 trials), "Molnupiravir" (2 trials), "Neuroimaging" (2 trials) and "Ocrelizumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Groupe Hospitalier Pellegrin" are 43 trials for "All" genders, 4 trials for "Male" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Groupe Hospitalier Pellegrin". undefined are not yet recruiting, 11 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 27 completed trials in Groupe Hospitalier Pellegrin, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Groupe Hospitalier Pellegrin, 2 "Phase 1" clinical trials were conducted, 12 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 10 trials that are defined as “Not Applicable".